PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Arne Skogvall | 33,13 | 33,13 | 2022-09-28 |
| Staffan Skogvall | 9,93 | 9,93 | 2022-10-18 |
| Avanza Pension | 1,65 | 1,65 | 2022-09-28 |
| Vict Th Engwalls Stiftelse | 1,63 | 1,63 | 2022-09-28 |
| Henrik Skog | 1,57 | 1,57 | 2022-09-28 |
| Arian Ismail | 1,30 | 1,30 | 2022-09-28 |
| Nordnet Pensionsförsäkring | 1,05 | 1,05 | 2022-09-28 |
| Staffan Engelbert Bodén | 0,80 | 0,80 | 2022-09-28 |
| Tommy Johansson | 0,67 | 0,67 | 2022-09-28 |
| Torsten Ingemar Jonsson | 0,67 | 0,67 | 2022-09-28 |
2023-02-16 Bokslutskommuniké 2022